Thomas Powles
托马斯·鲍尔斯
MBBS, MD, FRCP
Professor of Genitourinary Oncology; Director, Barts Cancer Centre泌尿生殖肿瘤学教授；巴茨癌症中心主任
👥Biography 个人简介
Thomas Powles is Europe's foremost urothelial cancer researcher, leading transformative trials of EV+pembrolizumab combination therapy. His work on the EV-302/KEYNOTE-A39 trial established this doublet as the new first-line standard in advanced urothelial carcinoma globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EV+Pembrolizumab Combination Therapy
Led EV-302/KEYNOTE-A39 trial showing enfortumab vedotin plus pembrolizumab dramatically improved overall survival versus chemotherapy as first-line advanced urothelial carcinoma treatment.
Urothelial Cancer International Research Leadership
Leads numerous European and global phase III trials in urothelial cancer, advancing checkpoint inhibitors, antibody-drug conjugates, and targeted therapies to regulatory approval.
Representative Works 代表性著作
Enfortumab Vedotin plus Pembrolizumab in Untreated Advanced Urothelial Cancer
New England Journal of Medicine (2024)
EV-302 trial demonstrating the EV+pembro combination reduced risk of death by 53% versus chemotherapy, establishing a new first-line standard of care.
Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma
New England Journal of Medicine (2020)
JAVELIN Bladder 100 trial showing avelumab maintenance after platinum chemotherapy significantly improved overall survival in advanced urothelial carcinoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 托马斯·鲍尔斯 的研究动态
Follow Thomas Powles's research updates
留下邮箱，当我们发布与 Thomas Powles（Barts Cancer Institute, Queen Mary University of London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment